clinical trial · NCT05629559
4D-310 in Adults With Fabry Disease and Cardiac Involvement
Fabry Disease4D-310
brief summary
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement
started
Oct 16, 2022
primary completion
Jun 1, 2026
completion
Jun 1, 2030
last updated
Feb 21, 2025
detailed description
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement
official title
An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol